[Out-patient management of nausea and vomiting in multiday therapy of acute myeloid leukemia in the elderly. Use of granisetron in slow-release transdermal formulation. Clinical case].

: Nausea and vomiting induced by chemotherapy (CINV) occur in 70-80% of onco-haematological patients undergoing antiblastic therapy. The anti-emetic therapy chosen according to the guidelines and characteristics of the single patient solve CINV in about 80% of cases. The concept of supportive care, which includes the treatment of CINV, has been formalized by the Multinational Association Supportive Care in Cancer (MASCC) to prevent and manage the side effects of antiblastic therapy. The evaluation of co-morbidities makes it possible to choose the most suitable antiemetic drug in compliance with multi-drug non-oncology therapies. The most immediate benefits are an improvement in the quality of life (QoL), a greater adherence of the patient to cancer therapy, and a lower interaction between drugs.